methylphenidate has been researched along with Depression, Involutional in 44 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Study durations ranged from 8 to 16 weeks and MPH dosing ranged from 5 to 90 mg per day." | 6.72 | Methylphenidate use in geriatric depression: A systematic review. ( Britt, RB; Brown, JN; Kahlon, CH; Smith, KR, 2021) |
| "To systematically review the literature on the therapeutic use of amphetamine, lisdexamfetamine and methylphenidate in elderly population with and without dementia." | 5.05 | Amphetamine Use in the Elderly: A Systematic Review of the Literature. ( Colpo, GD; John, V; Rocha, NP; Sassi, KLM; Teixeira, AL, 2020) |
| "The use of traditional psychostimulants (methylphenidate and dexamphetamine) and stimulant-like drugs (modafinil and armodafinil) for the treatment of depression is a growing concern given the lack of research evidence supporting their effectiveness." | 4.93 | Stimulants for depression: On the up and up? ( Bassett, D; Boyce, P; Byrow, Y; Hopwood, M; Lyndon, W; Malhi, GS; Mulder, R; Murray, G; Porter, R; Singh, A, 2016) |
| "Selegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation) resulting in non-selective MAOI activity at oral doses≥20 mg/day." | 3.01 | Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations. ( Birkenhager, TK; Caiazza, C; Cattaneo, CI; de Bartolomeis, A; Fornaro, M; Gillman, K; Iasevoli, F; Rossano, F; Ruhé, HG; Sobrino, A; Solini, N; Stahl, S; Van den Eynde, V; Vellucci, A; Zotti, N, 2023) |
| "It involved 88 terminally ill cancer patients from University of Malaya Medical Centre, Kuala Lumpur, Malaysia." | 2.79 | Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study. ( Boks, MP; de Wit, NJ; Ng, CG; Roes, KC; Sulaiman, AH; Tan, SB; Zainal, NZ, 2014) |
| "There was no difference in days of substance use or ADHD symptom outcomes over time in adolescents with MDD or those without MDD treated with OROS-MPH or placebo." | 2.77 | Major depression and treatment response in adolescents with ADHD and substance use disorder. ( Mikulich-Gilbertson, SK; Min, SJ; Riggs, PD; Tamm, L; Trello-Rishel, K; Warden, D; Winhusen, T, 2012) |
| "OROS methylphenidate was superior to placebo in improving apathy and fatigue as measured by the AES and the MAF." | 2.73 | Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. ( Binder, CE; Camacho, F; Fallu, A; Kennedy, SH; O'Donovan, MC; Ravindran, AV, 2008) |
| "Depression is a common morbidity after traumatic brain injury." | 2.72 | Therapeutic benefits of pharmacologic and nonpharmacologic treatments for depressive symptoms after traumatic brain injury: a systematic review and network meta-analysis. ( Carvalho, AF; Chen, TY; Chen, YW; Cheng, YS; Chu, CS; Hsu, CW; Lei, WT; Li, DJ; Liang, CS; Lin, PY; Stubbs, B; Sun, CK; Tseng, PT; Tu, YK; Wu, CK; Wu, MK; Wu, YC; Yeh, TC, 2021) |
| " Study durations ranged from 8 to 16 weeks and MPH dosing ranged from 5 to 90 mg per day." | 2.72 | Methylphenidate use in geriatric depression: A systematic review. ( Britt, RB; Brown, JN; Kahlon, CH; Smith, KR, 2021) |
| "Methylphenidate was tapered and discontinued during weeks 9 and 10." | 2.71 | Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. ( Kim, MD; Kumar, A; Lavretsky, H; Reynolds, CF, 2003) |
| "At 14 years after smoke inhalation injury, he had persistent cognitive impairment." | 1.38 | Progressive neuropsychiatric and brain abnormalities after smoke inhalation. ( Tobe, E, 2012) |
| "Psychiatrists treated major depressive disorder in advanced cancer patients on the basis of the algorithm." | 1.35 | Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. ( Akechi, T; Akizuki, N; Ito, T; Nakano, T; Okamura, M; Shimizu, K; Uchitomi, Y, 2008) |
| " However, patients may require dosage adjustment for tolerability of this combination." | 1.31 | Methylphenidate augmentation of citalopram in elderly depressed patients. ( Kumar, A; Lavretsky, H, 2001) |
| "The authors attempted to treat Major Depressive Disorder (MDD) suboptimally responsive to one of the newer (second-generation) antidepressants by augmentation with a psychostimulant medication." | 1.30 | Psychostimulant augmentation of second generation antidepressants: a case series. ( Anand, VS; Masand, PS; Tanquary, JF, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.55) | 18.7374 |
| 1990's | 2 (4.55) | 18.2507 |
| 2000's | 19 (43.18) | 29.6817 |
| 2010's | 17 (38.64) | 24.3611 |
| 2020's | 4 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Rossano, F | 1 |
| Caiazza, C | 1 |
| Sobrino, A | 1 |
| Solini, N | 1 |
| Vellucci, A | 1 |
| Zotti, N | 1 |
| Fornaro, M | 1 |
| Gillman, K | 1 |
| Cattaneo, CI | 1 |
| Van den Eynde, V | 1 |
| Birkenhager, TK | 1 |
| Ruhé, HG | 1 |
| Stahl, S | 1 |
| Iasevoli, F | 1 |
| de Bartolomeis, A | 1 |
| Sassi, KLM | 1 |
| Rocha, NP | 1 |
| Colpo, GD | 1 |
| John, V | 1 |
| Teixeira, AL | 1 |
| Cheng, YS | 1 |
| Tseng, PT | 1 |
| Wu, YC | 1 |
| Tu, YK | 1 |
| Wu, CK | 1 |
| Hsu, CW | 1 |
| Lei, WT | 1 |
| Li, DJ | 1 |
| Chen, TY | 1 |
| Stubbs, B | 1 |
| Carvalho, AF | 1 |
| Liang, CS | 1 |
| Yeh, TC | 1 |
| Chu, CS | 1 |
| Chen, YW | 1 |
| Lin, PY | 1 |
| Wu, MK | 1 |
| Sun, CK | 1 |
| Smith, KR | 1 |
| Kahlon, CH | 1 |
| Brown, JN | 1 |
| Britt, RB | 1 |
| McIntyre, RS | 1 |
| Lee, Y | 1 |
| Zhou, AJ | 1 |
| Rosenblat, JD | 1 |
| Peters, EM | 1 |
| Lam, RW | 1 |
| Kennedy, SH | 3 |
| Rong, C | 1 |
| Jerrell, JM | 1 |
| Feely, MA | 1 |
| Litin, SC | 1 |
| Bundrick, JB | 1 |
| Ng, CG | 1 |
| Boks, MP | 1 |
| Roes, KC | 1 |
| Zainal, NZ | 1 |
| Sulaiman, AH | 1 |
| Tan, SB | 1 |
| de Wit, NJ | 1 |
| Rizvi, SJ | 1 |
| Geraci, J | 1 |
| Ravindran, A | 1 |
| Lavretsky, H | 7 |
| Reinlieb, M | 1 |
| St Cyr, N | 1 |
| Siddarth, P | 4 |
| Ercoli, LM | 1 |
| Senturk, D | 1 |
| Nelson, JC | 2 |
| Roose, S | 1 |
| Rutherford, B | 1 |
| Eyre, HA | 1 |
| Eskin, A | 1 |
| Nelson, SF | 1 |
| St Cyr, NM | 1 |
| Baune, BT | 1 |
| Malhi, GS | 1 |
| Byrow, Y | 1 |
| Bassett, D | 1 |
| Boyce, P | 1 |
| Hopwood, M | 1 |
| Lyndon, W | 1 |
| Mulder, R | 1 |
| Porter, R | 1 |
| Singh, A | 1 |
| Murray, G | 1 |
| Waxmonsky, J | 1 |
| Pelham, WE | 1 |
| Gnagy, E | 1 |
| Cummings, MR | 1 |
| O'Connor, B | 1 |
| Majumdar, A | 1 |
| Verley, J | 1 |
| Hoffman, MT | 1 |
| Massetti, GA | 1 |
| Burrows-MacLean, L | 1 |
| Fabiano, GA | 1 |
| Waschbusch, DA | 1 |
| Chacko, A | 1 |
| Arnold, FW | 1 |
| Walker, KS | 1 |
| Garefino, AC | 1 |
| Robb, JA | 1 |
| Ng, B | 2 |
| Pae, CU | 2 |
| Patkar, AA | 2 |
| Masand, PS | 3 |
| Manor, I | 1 |
| Gutnik, I | 1 |
| Ben-Dor, DH | 1 |
| Apter, A | 1 |
| Sever, J | 1 |
| Tyano, S | 1 |
| Weizman, A | 1 |
| Zalsman, G | 1 |
| Frodl, T | 1 |
| Stauber, J | 1 |
| Schaaff, N | 1 |
| Koutsouleris, N | 1 |
| Scheuerecker, J | 1 |
| Ewers, M | 1 |
| Omerovic, M | 1 |
| Opgen-Rhein, M | 1 |
| Hampel, H | 1 |
| Reiser, M | 1 |
| Möller, HJ | 1 |
| Meisenzahl, E | 1 |
| Park, YM | 1 |
| Jung, YK | 1 |
| Biederman, J | 1 |
| Spencer, TJ | 1 |
| Monuteaux, MC | 1 |
| Faraone, SV | 1 |
| Warden, D | 1 |
| Riggs, PD | 1 |
| Min, SJ | 1 |
| Mikulich-Gilbertson, SK | 1 |
| Tamm, L | 1 |
| Trello-Rishel, K | 1 |
| Winhusen, T | 1 |
| Howland, RH | 1 |
| Tobe, E | 1 |
| Niederhofer, H | 1 |
| MORGAN, DR | 1 |
| Janowsky, DS | 1 |
| Kim, MD | 1 |
| Kumar, A | 4 |
| Reynolds, CF | 3 |
| Padala, PR | 2 |
| Petty, F | 2 |
| Bhatia, SC | 2 |
| Park, S | 1 |
| Peindl, K | 1 |
| Hooper-Wood, C | 1 |
| Mannelli, P | 1 |
| Ciccone, P | 1 |
| Burke, WJ | 1 |
| Okamura, M | 1 |
| Akizuki, N | 1 |
| Nakano, T | 1 |
| Shimizu, K | 1 |
| Ito, T | 1 |
| Akechi, T | 1 |
| Uchitomi, Y | 1 |
| Levin, FR | 1 |
| Bisaga, A | 1 |
| Raby, W | 1 |
| Aharonovich, E | 1 |
| Rubin, E | 1 |
| Mariani, J | 1 |
| Brooks, DJ | 1 |
| Garawi, F | 1 |
| Nunes, EV | 1 |
| Ravindran, AV | 1 |
| O'Donovan, MC | 1 |
| Fallu, A | 1 |
| Camacho, F | 1 |
| Binder, CE | 1 |
| Mantani, A | 1 |
| Fujikawa, T | 1 |
| Ohmori, N | 1 |
| Yamawaki, S | 1 |
| Ishii, M | 1 |
| Tatsuzawa, Y | 1 |
| Yoshino, A | 1 |
| Nomura, S | 1 |
| Anand, VS | 1 |
| Tanquary, JF | 1 |
| Schaller, JL | 1 |
| Behar, D | 1 |
| Eggers, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Parallel-group, Double-blind, Placebo-controlled Study of Methylphenidate as an Add on Therapy for Mirtazapine in the Treatment of Major Depressive Disorder in Cancer Patients Under Palliative Care[NCT01497548] | Phase 3 | 120 participants (Anticipated) | Interventional | 2011-03-31 | Recruiting | ||
| The Use of Methylphenidate to Improve Clinical Outcomes in Geriatric Depression: A Double-blind Placebo-Controlled Trial of Methylphenidate (Ritalin) Augmentation of Citalopram (Celexa) in Depressed Elderly Patients[NCT00602290] | Phase 4 | 181 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| A Double-blind, Placebo-controlled, Randomized Trial to Evaluate the Safety, Tolerability and Efficacy of CONCERTA® (Methylphenidate Hydrochloride) Augmentation of SSRI/SNRI Monotherapy in Adult Patients With Major Depressive Disorder.[NCT00246233] | Phase 3 | 145 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Hamilton Depression Rating Scale (HDRS) is a 24-item depression scale and the total score is summed with a minimum score=0 and maximum score=76. There are no subscales and the higher values represent a worse outcome. Outcomes are measured and defined as follows: 1) Response will be defined as HDRS scores of 10 or less; 2) Sustained response will be defined as maintained response at week 16; 4) Remission will be defined as HDRS scores of 6 or less. (NCT00602290)
Timeframe: Maintained response measured at Week 16
| Intervention | units on a scale (Mean) |
|---|---|
| 1 - Citalopram + Placebo | 18.3 |
| 2 - Methylphenidate + Placebo | 18.7 |
| 3 - Methylphenidate + Citalopram | 19.8 |
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) is a 16 item self-administered questionnaire that captures life satisfaction over the past week. Each question is rated on a 5 point scale from 1 (Very Poor) to 5 (Very Good). The total score is reported for items 1-14. The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70 with higher values representing a better outcome. (NCT00602290)
Timeframe: Measured at Baseline and Week 16
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| 1 - Citalopram + Placebo | 45.50 | 54.45 |
| 2 - Methylphenidate + Placebo | 47.06 | 53.54 |
| 3 - Methylphenidate + Citalopram | 47.52 | 57.79 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
9 reviews available for methylphenidate and Depression, Involutional
| Article | Year |
|---|---|
Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations.
Topics: Attention Deficit Disorder with Hyperactivity; Depressive Disorder, Major; Humans; Methylphenidate; | 2023 |
Amphetamine Use in the Elderly: A Systematic Review of the Literature.
Topics: Aged; Amphetamine; Dementia; Depressive Disorder, Major; Humans; Lisdexamfetamine Dimesylate; Methyl | 2020 |
Therapeutic benefits of pharmacologic and nonpharmacologic treatments for depressive symptoms after traumatic brain injury: a systematic review and network meta-analysis.
Topics: Brain Injuries, Traumatic; Depression; Depressive Disorder, Major; Humans; Methylphenidate; Network | 2021 |
Methylphenidate use in geriatric depression: A systematic review.
Topics: Aged; Citalopram; Depression; Depressive Disorder, Major; Humans; Methylphenidate; Middle Aged; Pros | 2021 |
The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Dextroamphetami | 2017 |
Stimulants for depression: On the up and up?
Topics: Amphetamine; Antidepressive Agents; Benzhydryl Compounds; Bipolar Disorder; Central Nervous System S | 2016 |
Depression and dysphoria effects on the interpersonal perception of negative and positive moods and caring relationships: effects of antidepressants, amphetamine, and methylphenidate.
Topics: Amphetamine; Antidepressive Agents; Anxiety Disorders; Central Nervous System Stimulants; Clinical T | 2003 |
Augmentation strategies in the treatment of major depressive disorder. Recent findings and current status of augmentation strategies.
Topics: Antidepressive Agents; Delayed-Action Preparations; Depressive Disorder, Major; Drug Synergism; Drug | 2007 |
[Psychotropic drug therapy in children].
Topics: Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; | 1977 |
12 trials available for methylphenidate and Depression, Involutional
| Article | Year |
|---|---|
Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study.
Topics: Academic Medical Centers; Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and St | 2014 |
Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder: effects of apathy/anhedonia and fatigue.
Topics: Adolescent; Adult; Aged; Anhedonia; Apathy; Central Nervous System Stimulants; Depressive Disorder, | 2014 |
Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Anxiety Disorders; Apathy; Citalopram; Cognition Disorders; Depressive Disorder, Major; Double | 2015 |
Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dopamine Upt | 2016 |
The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation.
Topics: Assertiveness; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous Syst | 2008 |
Major depression and treatment response in adolescents with ADHD and substance use disorder.
Topics: Adolescent; Alcohol-Related Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2012 |
Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Central Nervous System Stimulants | 2003 |
Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial.
Topics: Aged; Central Nervous System Stimulants; Citalopram; Cognition Disorders; Depressive Disorder, Major | 2006 |
A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Central Nervous System Stimulants; Delayed-Action Pr | 2006 |
Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cocaine-Rel | 2008 |
The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression: a pilot study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Central Nervous System Stimulants | 2008 |
Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Depressive Disorder, Major; Diagnos | 2008 |
Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Depressive Disorder, Major; Diagnos | 2008 |
Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Depressive Disorder, Major; Diagnos | 2008 |
Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Depressive Disorder, Major; Diagnos | 2008 |
23 other studies available for methylphenidate and Depression, Involutional
| Article | Year |
|---|---|
Clinical Pearls in palliative medicine.
Topics: Adult; Advance Care Planning; Aged; Antiemetics; Baclofen; Benzodiazepines; Constipation; Depressive | 2017 |
The role of stimulants in late-life depression.
Topics: Citalopram; Depressive Disorder, Major; Female; Humans; Male; Methylphenidate | 2015 |
Response to Roose and Rutherford.
Topics: Citalopram; Depressive Disorder, Major; Female; Humans; Male; Methylphenidate | 2015 |
Cardiac Effects of Methylphenidate.
Topics: Citalopram; Depressive Disorder, Major; Female; Humans; Male; Methylphenidate | 2015 |
Is there a role for psychostimulants in old age depression and apathy?
Topics: Aged; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Dis | 2009 |
Augmentation of dopaminergic agents for major depressive disorder.
Topics: Administration, Oral; Benzhydryl Compounds; Central Nervous System Stimulants; Combined Modality The | 2009 |
Possible association between attention deficit hyperactivity disorder and attempted suicide in adolescents - a pilot study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorb | 2010 |
Amygdala reduction in patients with ADHD compared with major depression and healthy volunteers.
Topics: Amygdala; Attention Deficit Disorder with Hyperactivity; Brain; Cross-Sectional Studies; Depressive | 2010 |
Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression.
Topics: Adolescent; Bipolar Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Male; M | 2010 |
A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects.
Topics: Adolescent; Age Factors; Aging; Attention Deficit Disorder with Hyperactivity; Body Height; Body Wei | 2010 |
The use of dopaminergic and stimulant drugs for the treatment of depression.
Topics: Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2012 |
Progressive neuropsychiatric and brain abnormalities after smoke inhalation.
Topics: Activities of Daily Living; Brain; Cognition Disorders; Depressive Disorder, Major; DNA Damage; Fluo | 2012 |
[Therapy refractory depression: symptom improvement after antidepressant and methylphenidate combination therapy].
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; | 2002 |
Largactil, ritalin and meratran in the treatment of endogenous psychotic depression.
Topics: Bipolar Disorder; Chlorpromazine; Depression; Depressive Disorder, Major; Methylphenidate; Piperidin | 1957 |
Methylphenidate may treat apathy independent of depression.
Topics: Affective Symptoms; Central Nervous System Stimulants; Depressive Disorder, Major; Female; Humans; M | 2005 |
Treatment of apathy with methylphenidate.
Topics: Aged; Central Nervous System Stimulants; Dementia, Vascular; Depressive Disorder, Major; Drive; Fema | 2007 |
Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer.
Topics: Adult; Aged; Algorithms; Alprazolam; Amitriptyline; Antidepressive Agents; Anxiety Disorders; Benzod | 2008 |
Methylphenidate and depression.
Topics: Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Delayed-Action Prepa | 2008 |
Methylphenidate in the treatment of geriatric patients with vascular depression: a retrospective chart review.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Central Nervous System Stimulants; Depressive Disord | 2008 |
Serotonin syndrome induced by augmentation of SSRI with methylphenidate.
Topics: Central Nervous System Stimulants; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Comb | 2008 |
Psychostimulant augmentation of second generation antidepressants: a case series.
Topics: Adult; Antidepressive Agents, Second-Generation; Central Nervous System Stimulants; Depressive Disor | 1998 |
Treating comorbid ADHD, major depression, and panic.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clonazepam; | 1999 |
Methylphenidate augmentation of citalopram in elderly depressed patients.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Central Nervous System Stimulants; Citalopram; Depre | 2001 |